First Header Logo Second Header Logo

Connection

Bayard Powell to Prognosis

Back to Details
This is a "connection" page, showing publications Bayard Powell has written about Prognosis.
Bayard Powell
Connection Strength
1.100
Prognosis
  1. Walker CJ, Kohlschmidt J, Eisfeld AK, Mrózek K, Liyanarachchi S, Song C, Nicolet D, Blachly JS, Bill M, Papaioannou D, Oakes CC, Giacopelli B, Genutis LK, Maharry SE, Orwick S, Archer KJ, Powell BL, Kolitz JE, Uy GL, Wang ES, Carroll AJ, Stone RM, Byrd JC, de la Chapelle A, Bloomfield CD. Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia. Clin Cancer Res. 2019 11 01; 25(21):6524-6531.
    View in: PubMed
    Score: 0.132
  2. Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Pardee TS, Ellis LR, Powell BL. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood. 2013 May 23; 121(21):4287-94.
    View in: PubMed
    Score: 0.085
  3. Mrózek K, Eisfeld AK, Kohlschmidt J, Carroll AJ, Walker CJ, Nicolet D, Blachly JS, Bill M, Papaioannou D, Wang ES, Uy GL, Kolitz JE, Powell BL, Blum W, Stone RM, Byrd JC, Bloomfield CD. Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically. Leukemia. 2019 07; 33(7):1620-1634.
    View in: PubMed
    Score: 0.032
  4. Kuhlman P, Isom S, Pardee TS, Burns C, Tawfik B, Lamar ZS, Powell BL, Klepin HD. Association between glycemic control, age, and outcomes among intensively treated patients with acute myeloid leukemia. Support Care Cancer. 2019 Aug; 27(8):2877-2884.
    View in: PubMed
    Score: 0.032
  5. Kutny MA, Geyer S, Laumann KM, Gregory J, Willman CL, Stock W, Larson RA, Powell BL, Feusner JH. Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance). Pediatr Blood Cancer. 2019 03; 66(3):e27542.
    View in: PubMed
    Score: 0.031
  6. Eisfeld AK, Kohlschmidt J, Mrózek K, Mims A, Walker CJ, Blachly JS, Nicolet D, Orwick S, Maharry SE, Carroll AJ, Powell BL, Kolitz JE, Wang ES, Stone RM, de la Chapelle A, Byrd JC, Bloomfield CD. NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. Leukemia. 2018 12; 32(12):2536-2545.
    View in: PubMed
    Score: 0.030
  7. Eisfeld AK, Kohlschmidt J, Mrózek K, Blachly JS, Walker CJ, Nicolet D, Orwick S, Maharry SE, Carroll AJ, Stone RM, de la Chapelle A, Wang ES, Kolitz JE, Powell BL, Byrd JC, Bloomfield CD. Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia. 2018 06; 32(6):1338-1348.
    View in: PubMed
    Score: 0.030
  8. Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mittelman M, Muus P, Nimer SD, Hellström-Lindberg E, Powell BL, Guerci-Bresler A, Sekeres MA, Deeg HJ, Del Cañizo C, Greenberg PL, Shammo JM, Skikne B, Yu X, List AF. Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q). J Hematol Oncol. 2017 06 26; 10(1):131.
    View in: PubMed
    Score: 0.028
  9. Papaioannou D, Shen C, Nicolet D, McNeil B, Bill M, Karunasiri M, Burke MH, Ozer HG, Yilmaz SA, Zitzer N, Behbehani GK, Oakes CC, Steiner DJ, Marcucci G, Powell BL, Kolitz JE, Carter TH, Wang ES, Mrózek K, Croce CM, Caligiuri MA, Bloomfield CD, Garzon R, Dorrance AM. Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia. Proc Natl Acad Sci U S A. 2017 06 06; 114(23):E4641-E4647.
    View in: PubMed
    Score: 0.028
  10. Papaioannou D, Nicolet D, Volinia S, Mrózek K, Yan P, Bundschuh R, Carroll AJ, Kohlschmidt J, Blum W, Powell BL, Uy GL, Kolitz JE, Wang ES, Eisfeld AK, Orwick SJ, Lucas DM, Caligiuri MA, Stone RM, Byrd JC, Garzon R, Bloomfield CD. Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia. Haematologica. 2017 08; 102(8):1391-1400.
    View in: PubMed
    Score: 0.028
  11. Mantha S, Goldman DA, Devlin SM, Lee JW, Zannino D, Collins M, Douer D, Iland HJ, Litzow MR, Stein EM, Appelbaum FR, Larson RA, Stone R, Powell BL, Geyer S, Laumann K, Rowe JM, Erba H, Coutre S, Othus M, Park JH, Wiernik PH, Tallman MS. Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Blood. 2017 Mar 30; 129(13):1763-1767.
    View in: PubMed
    Score: 0.028
  12. Eisfeld AK, Kohlschmidt J, Schwind S, Nicolet D, Blachly JS, Orwick S, Shah C, Bainazar M, Kroll KW, Walker CJ, Carroll AJ, Powell BL, Stone RM, Kolitz JE, Baer MR, de la Chapelle A, Mrózek K, Byrd JC, Bloomfield CD. Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia. Leukemia. 2017 06; 31(6):1278-1285.
    View in: PubMed
    Score: 0.027
  13. Niederwieser C, Nicolet D, Carroll AJ, Kolitz JE, Powell BL, Kohlschmidt J, Stone RM, Byrd JC, Mrózek K, Bloomfield CD. Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance). Haematologica. 2016 12; 101(12):1516-1523.
    View in: PubMed
    Score: 0.027
  14. Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, Pigneux A, Wetzler M, Stuart RK, Erba HP, Damon LE, Powell BL, Lindeman N, Steensma DP, Wadleigh M, DeAngelo DJ, Neuberg D, Stone RM, Ebert BL. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015 Feb 26; 125(9):1367-76.
    View in: PubMed
    Score: 0.024
  15. Niederwieser C, Kohlschmidt J, Volinia S, Whitman SP, Metzeler KH, Eisfeld AK, Maharry K, Yan P, Frankhouser D, Becker H, Schwind S, Carroll AJ, Nicolet D, Mendler JH, Curfman JP, Wu YZ, Baer MR, Powell BL, Kolitz JE, Moore JO, Carter TH, Bundschuh R, Larson RA, Stone RM, Mrózek K, Marcucci G, Bloomfield CD. Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. Leukemia. 2015 Mar; 29(3):567-75.
    View in: PubMed
    Score: 0.023
  16. Elliot K, Tooze JA, Geller R, Powell BL, Pardee TS, Ritchie E, Kennedy L, Callahan KE, Klepin HD. The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML). Leuk Res. 2014 Oct; 38(10):1184-90.
    View in: PubMed
    Score: 0.023
  17. Becker H, Maharry K, Mrózek K, Volinia S, Eisfeld AK, Radmacher MD, Kohlschmidt J, Metzeler KH, Schwind S, Whitman SP, Mendler JH, Wu YZ, Nicolet D, Paschka P, Powell BL, Carter TH, Wetzler M, Kolitz JE, Carroll AJ, Baer MR, Caligiuri MA, Stone RM, Marcucci G, Bloomfield CD. Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8. Leukemia. 2014 Aug; 28(8):1754-1758.
    View in: PubMed
    Score: 0.023
  18. Poiré X, Moser BK, Gallagher RE, Laumann K, Bloomfield CD, Powell BL, Koval G, Gulati K, Holowka N, Larson RA, Tallman MS, Appelbaum FR, Sher D, Willman C, Paietta E, Stock W. Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. Leuk Lymphoma. 2014 Jul; 55(7):1523-32.
    View in: PubMed
    Score: 0.023
  19. Marcucci G, Yan P, Maharry K, Frankhouser D, Nicolet D, Metzeler KH, Kohlschmidt J, Mrózek K, Wu YZ, Bucci D, Curfman JP, Whitman SP, Eisfeld AK, Mendler JH, Schwind S, Becker H, Bär C, Carroll AJ, Baer MR, Wetzler M, Carter TH, Powell BL, Kolitz JE, Byrd JC, Plass C, Garzon R, Caligiuri MA, Stone RM, Volinia S, Bundschuh R, Bloomfield CD. Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. J Clin Oncol. 2014 Feb 20; 32(6):548-56.
    View in: PubMed
    Score: 0.022
  20. Whitman SP, Kohlschmidt J, Maharry K, Volinia S, Mrózek K, Nicolet D, Schwind S, Becker H, Metzeler KH, Mendler JH, Eisfeld AK, Carroll AJ, Powell BL, Carter TH, Baer MR, Kolitz JE, Park IK, Stone RM, Caligiuri MA, Marcucci G, Bloomfield CD. GAS6 expression identifies high-risk adult AML patients: potential implications for therapy. Leukemia. 2014 Jun; 28(6):1252-1258.
    View in: PubMed
    Score: 0.022
  21. Metzeler KH, Maharry K, Kohlschmidt J, Volinia S, Mrózek K, Becker H, Nicolet D, Whitman SP, Mendler JH, Schwind S, Eisfeld AK, Wu YZ, Powell BL, Carter TH, Wetzler M, Kolitz JE, Baer MR, Carroll AJ, Stone RM, Caligiuri MA, Marcucci G, Bloomfield CD. A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia. Leukemia. 2013 Oct; 27(10):2023-31.
    View in: PubMed
    Score: 0.022
  22. Eisfeld AK, Marcucci G, Maharry K, Schwind S, Radmacher MD, Nicolet D, Becker H, Mrózek K, Whitman SP, Metzeler KH, Mendler JH, Wu YZ, Liyanarachchi S, Patel R, Baer MR, Powell BL, Carter TH, Moore JO, Kolitz JE, Wetzler M, Caligiuri MA, Larson RA, Tanner SM, de la Chapelle A, Bloomfield CD. miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. Blood. 2012 Jul 12; 120(2):249-58.
    View in: PubMed
    Score: 0.020
  23. Kutny MA, Moser BK, Laumann K, Feusner JH, Gamis A, Gregory J, Larson RA, Powell BL, Stock W, Willman CL, Woods WG, Meshinchi S. FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2012 Oct; 59(4):662-7.
    View in: PubMed
    Score: 0.020
  24. Whitman SP, Caligiuri MA, Maharry K, Radmacher MD, Kohlschmidt J, Becker H, Mrózek K, Wu YZ, Schwind S, Metzeler KH, Mendler JH, Wen J, Baer MR, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Larson RA, Marcucci G, Bloomfield CD. The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia. Leukemia. 2012 Jul; 26(7):1713-7.
    View in: PubMed
    Score: 0.020
  25. Marcucci G, Metzeler KH, Schwind S, Becker H, Maharry K, Mrózek K, Radmacher MD, Kohlschmidt J, Nicolet D, Whitman SP, Wu YZ, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Moore JO, Caligiuri MA, Larson RA, Bloomfield CD. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2012 Mar 01; 30(7):742-50.
    View in: PubMed
    Score: 0.020
  26. Walter RB, Medeiros BC, Powell BL, Schiffer CA, Appelbaum FR, Estey EH. Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia. Haematologica. 2012 May; 97(5):739-42.
    View in: PubMed
    Score: 0.019
  27. Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mrózek K, Nicolet D, Whitman SP, Wu YZ, Schwind S, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood. 2011 Dec 22; 118(26):6920-9.
    View in: PubMed
    Score: 0.019
  28. Becker H, Maharry K, Radmacher MD, Mrózek K, Metzeler KH, Whitman SP, Schwind S, Kohlschmidt J, Wu YZ, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Moore JO, Caligiuri MA, Larson RA, Marcucci G, Bloomfield CD. Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Haematologica. 2011 Oct; 96(10):1488-95.
    View in: PubMed
    Score: 0.019
  29. Schwind S, Maharry K, Radmacher MD, Mrózek K, Holland KB, Margeson D, Whitman SP, Hickey C, Becker H, Metzeler KH, Paschka P, Baldus CD, Liu S, Garzon R, Powell BL, Kolitz JE, Carroll AJ, Caligiuri MA, Larson RA, Marcucci G, Bloomfield CD. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010 Dec 20; 28(36):5257-64.
    View in: PubMed
    Score: 0.018
  30. Whitman SP, Maharry K, Radmacher MD, Becker H, Mrózek K, Margeson D, Holland KB, Wu YZ, Schwind S, Metzeler KH, Wen J, Baer MR, Powell BL, Carter TH, Kolitz JE, Wetzler M, Moore JO, Stone RM, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010 Nov 04; 116(18):3622-6.
    View in: PubMed
    Score: 0.018
  31. Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, Whitman SP, Paschka P, Holland KB, Schwind S, Wu YZ, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Moore JO, Caligiuri MA, Larson RA, Bloomfield CD. Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010 Aug 05; 116(5):788-92.
    View in: PubMed
    Score: 0.017
  32. Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, Whitman SP, Wu YZ, Schwind S, Paschka P, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol. 2010 Feb 01; 28(4):596-604.
    View in: PubMed
    Score: 0.017
  33. Langer C, Marcucci G, Holland KB, Radmacher MD, Maharry K, Paschka P, Whitman SP, Mrózek K, Baldus CD, Vij R, Powell BL, Carroll AJ, Kolitz JE, Caligiuri MA, Larson RA, Bloomfield CD. Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol. 2009 Jul 01; 27(19):3198-204.
    View in: PubMed
    Score: 0.016
  34. Paschka P, Marcucci G, Ruppert AS, Whitman SP, Mrózek K, Maharry K, Langer C, Baldus CD, Zhao W, Powell BL, Baer MR, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol. 2008 Oct 01; 26(28):4595-602.
    View in: PubMed
    Score: 0.015
  35. Marcucci G, Radmacher MD, Maharry K, Mrózek K, Ruppert AS, Paschka P, Vukosavljevic T, Whitman SP, Baldus CD, Langer C, Liu CG, Carroll AJ, Powell BL, Garzon R, Croce CM, Kolitz JE, Caligiuri MA, Larson RA, Bloomfield CD. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008 May 01; 358(18):1919-28.
    View in: PubMed
    Score: 0.015
  36. Langer C, Radmacher MD, Ruppert AS, Whitman SP, Paschka P, Mrózek K, Baldus CD, Vukosavljevic T, Liu CG, Ross ME, Powell BL, de la Chapelle A, Kolitz JE, Larson RA, Marcucci G, Bloomfield CD. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood. 2008 Jun 01; 111(11):5371-9.
    View in: PubMed
    Score: 0.015
  37. Whitman SP, Ruppert AS, Radmacher MD, Mrózek K, Paschka P, Langer C, Baldus CD, Wen J, Racke F, Powell BL, Kolitz JE, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood. 2008 Feb 01; 111(3):1552-9.
    View in: PubMed
    Score: 0.015
  38. Marcucci G, Maharry K, Whitman SP, Vukosavljevic T, Paschka P, Langer C, Mrózek K, Baldus CD, Carroll AJ, Powell BL, Kolitz JE, Larson RA, Bloomfield CD. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol. 2007 Aug 01; 25(22):3337-43.
    View in: PubMed
    Score: 0.014
  39. Marcucci G, Baldus CD, Ruppert AS, Radmacher MD, Mrózek K, Whitman SP, Kolitz JE, Edwards CG, Vardiman JW, Powell BL, Baer MR, Moore JO, Perrotti D, Caligiuri MA, Carroll AJ, Larson RA, de la Chapelle A, Bloomfield CD. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol. 2005 Dec 20; 23(36):9234-42.
    View in: PubMed
    Score: 0.013
  40. Marcucci G, Mrózek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, Mayer RJ, Pettenati MJ, Powell BL, Edwards CG, Sterling LJ, Vardiman JW, Schiffer CA, Carroll AJ, Larson RA, Bloomfield CD. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol. 2005 Aug 20; 23(24):5705-17.
    View in: PubMed
    Score: 0.013
  41. Moore JO, George SL, Dodge RK, Amrein PC, Powell BL, Kolitz JE, Baer MR, Davey FR, Bloomfield CD, Larson RA, Schiffer CA. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood. 2005 May 01; 105(9):3420-7.
    View in: PubMed
    Score: 0.012
  42. Farag SS, Ruppert AS, Mrózek K, Mayer RJ, Stone RM, Carroll AJ, Powell BL, Moore JO, Pettenati MJ, Koduru PR, Stamberg J, Baer MR, Block AW, Vardiman JW, Kolitz JE, Schiffer CA, Larson RA, Bloomfield CD. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol. 2005 Jan 20; 23(3):482-93.
    View in: PubMed
    Score: 0.012
  43. Farag SS, Ruppert AS, Mrózek K, Carroll AJ, Pettenati MJ, Le Beau MM, Peterson BL, Powell BL, Ozer H, Silver RT, Larson RA, Bloomfield CD. Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study. Int J Oncol. 2004 Jul; 25(1):143-51.
    View in: PubMed
    Score: 0.012
  44. Frankel AE, Fleming DR, Hall PD, Powell BL, Black JH, Leftwich C, Gartenhaus R. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 1):3555-61.
    View in: PubMed
    Score: 0.011
  45. Baldus CD, Tanner SM, Ruppert AS, Whitman SP, Archer KJ, Marcucci G, Caligiuri MA, Carroll AJ, Vardiman JW, Powell BL, Allen SL, Moore JO, Larson RA, Kolitz JE, de la Chapelle A, Bloomfield CD. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood. 2003 Sep 01; 102(5):1613-8.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.